| Zeit | Aktuelle Nachrichten
| | Leser | Medien |
|---|
| 09.02.
| pSivida Corp. - 10-Q, Quarterly Report | | 9 | SEC Filings |
| 09.02.
| Psivida Corp Exploration Update | | 20 | wotnews |
| 08.02.
| pSivida Corp. Reports Results for the Second Quarter Ended December 31, 2011 | | 27 | Business Wire |
| pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in developing
sustained release, drug delivery products for treatment of
back-of-the-eye diseases, today announced financial...
Mehr lesen zu:
pSivida Corp. Reports Results for the Second Quarter Ended December 31, 2011 | |
| 07.02.
| Psivida Corp Company Reports - Other | | 34 | wotnews |
| 06.02.
| pSivida CEO to Present at 14th Annual BioCEO & Investor Conference February 14 | | 42 | Business Wire |
| pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in developing sustained
release, drug delivery products for treatment of back-of-the-eye
diseases, today announced that...
Mehr lesen zu:
pSivida CEO to Present at 14th Annual BioCEO & Investor Conference February 14 | |
| 03.02.
| pSivida Corporation shares up 11.54%, CEO takes seat on international glaucoma panel | | 39 | Proactive Investors |
| 02.02.
| pSivida CEO to Participate in Panel at Glaucoma 360 Conference February 3 | | 38 | Business Wire |
| pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in developing sustained
release, drug delivery products for treatment of back-of-the-eye
diseases, today announced that...
Mehr lesen zu:
pSivida CEO to Participate in Panel at Glaucoma 360 Conference February 3 | |
| 02.02.
| Psivida Corp Exploration Update | | 27 | wotnews |
| 01.02.
| pSivida Corp Announces Second Quarter 2012 Financial Results Release Date and Conference Call Information | | 41 | Business Wire |
| pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in developing sustained
release, drug delivery products for treatment of back-of-the-eye
diseases, today announced that...
Mehr lesen zu:
pSivida Corp Announces Second Quarter 2012 Financial Results Release Date and Conference Call Information | |
| 29.12.
| Psivida Corp Exploration Update | | 97 | wotnews |
| 27.12.
| pSivida Corp. - 10-K/A, Annual Report | | 30 | SEC Filings |
| 09.12.
| Psivida Corp releases Quarterly Report | | 103 | wotnews |
| 09.12.
| Psivida Corp Trading Halt | | 87 | wotnews |
| 02.12.
| Psivida Corp Mergers, acquisitions, takeovers | | 91 | wotnews |
| 01.12.
| Psivida Corp Results of Meeting | | 50 | wotnews |
| 22.11.
| pSivida (PSDV) Enters Evaluation Agreement with Leading Pharma Co. for Durasert(TM) | | 14 | StreetInsider.com |
| 22.11.
| pSivida Announces Tech Evaluation Agreement with Leading Pharmaceutical Company | | 64 | Business Wire |
| pSivida Corp. (NASDAQ:PSDV; ASX:PVA), a leader in developing sustained
release, drug delivery products for treatment of back-of-the-eye
diseases, today announced that...
Mehr lesen zu:
pSivida Announces Tech Evaluation Agreement with Leading Pharmaceutical Company | |
| 11.11.
| pSivida Corp. to Hold Monday November 14 Conference Call to Discuss Complete Response Letter for ILUVIEN® for DME and pSivida's Product Pipeline | | 83 | Business Wire |
| pSivida Corp. (NASDAQ:PSDV, ASX:PVA), a leader in developing sustained
release, drug delivery products for treatment of back-of-the-eye
diseases, today announced that...
Mehr lesen zu:
pSivida Corp. to Hold Monday November 14 Conference Call to Discuss Complete Response Letter for ILUVIEN® for DME and pSivida's Product Pipeline | |
| 11.11.
| pSivida (PSDV) Issues Statment on ILUVIEN NDA Decision by FDA | | 27 | StreetInsider.com |
| 11.11.
| pSivida Reports Receipt by Alimera Sciences of Complete Response Letter from FDA for ILUVIEN® for DME | | 103 | Business Wire |
| pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in developing
sustained release, drug delivery products for treatment of
back-of-the-eye diseases, today reported that...
Mehr lesen zu:
pSivida Reports Receipt by Alimera Sciences of Complete Response Letter from FDA for ILUVIEN® for DME | |
